Molecular structure of NVP-BVU972, CAS Number: 1185763-69-2
NVP-BVU972 (CAS 1185763-69-2)
Application:
NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM)
CAS Number:
1185763-69-2
Molecular Weight:
340.38
Molecular Formula:
C20H16N6
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
NVP-BVU972 is a selective and potent Met inhibitor (IC50 = 14 nM).
NVP-BVU972 (CAS 1185763-69-2) References
- A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. | Tiedt, R., et al. 2011. Cancer Res. 71: 5255-64. PMID: 21697284
- NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants. | Shin, JS., et al. 2014. Invest New Drugs. 32: 389-99. PMID: 24173966
- The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms? | Boissinot, M., et al. 2014. Cancers (Basel). 6: 1631-69. PMID: 25119536
- Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. | Li, A., et al. 2017. Clin Cancer Res. 23: 4929-4937. PMID: 28396313
- Pharmacophore Mapping Approach for Drug Target Identification: A Chemical Synthesis and in Silico Study on Novel Thiadiazole Compounds. | Meshram, RJ., et al. 2017. J Clin Diagn Res. 11: KF01-KF08. PMID: 28658808
- Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. | Kang, J., et al. 2018. J Thorac Oncol. 13: e49-e53. PMID: 29128427
- Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. | Fujino, T., et al. 2019. J Thorac Oncol. 14: 1753-1765. PMID: 31279006
- A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance. | Zahra, R., et al. 2020. PLoS One. 15: e0233993. PMID: 32484843
- Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment. | Wang, C., et al. 2022. J Med Chem. 65: 15140-15164. PMID: 36355693
- Macrocyclization strategy for improving candidate profiles in medicinal chemistry. | Darlami, O., et al. 2024. Eur J Med Chem. 272: 116501. PMID: 38754142
Inhibitor of:
Met.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NVP-BVU972, 10 mg | sc-364555 | 10 mg | $555.00 | |||
NVP-BVU972, 50 mg | sc-364555A | 50 mg | $1606.00 |